Patent: 7,087,621
✉ Email this page to a colleague
Summary for Patent: 7,087,621
| Title: | Benzo- and azabenzodithiazole compounds |
| Abstract: | The present invention provides compounds of formula I ##STR00001## or a pharmaceutically acceptable salt, solvate, prodrug or isomer thereof and compounds of the formula ##STR00002## or a pharmaceutically acceptable salt, solvate, prodrug or isomer thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors. |
| Inventor(s): | Sang; Xiaopeng (Glastonbury, CT), Du; Xuhua Karen (Cheshire, CT), Kadow; John F. (Wallingford, CT) |
| Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
| Application Number: | 10/933,094 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,087,621
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2023-09-05 |
| Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2023-09-05 |
| Genentech, Inc. | AVASTIN | bevacizumab | Injection | 125085 | 02/26/2004 | ⤷ Try a Trial | 2023-09-05 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
